The AUC was 0.822 when Exo‐GAS5 was used to distinguish patients with early-stage NSCLC, and further analysis implied that Exo‐GAS5 combined with CEA improved the AUC to 0.929. This evidence concerns the gene GAS5 and non-small cell lung carcinoma.